Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Evrysdi / risdiplam for treating spinal muscular atrophy as of December 2023

MARA Rating Company December 16, 2025

Litfulo / ritlecitinib for treating severe alopecia areata in people 12 years and over as of March 2024

MARA Rating Company December 16, 2025

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation as of July 2021

MARA Rating Company December 16, 2025

Romosozumab / evenity for treating severe osteoporosis in people after menopause who are at high risk of fracture as of May 2022

MARA Rating Company December 16, 2025

Roxadustat / evrenzo for treating symptomatic anaemia in chronic kidney disease as of July 2022

MARA Rating Company December 16, 2025

Ranibizumab / lucentis for treating choroidal neovascularisation associated with pathological myopia as of May 2024

MARA Rating Company December 16, 2025

Ultomiris / ravulizumab for treating paroxysmal nocturnal haemoglobinuria as of May 2021

MARA Rating Company December 16, 2025

Ravulizumab / ultomiris for treating atypical haemolytic uraemic syndrome as of June 2021

MARA Rating Company December 16, 2025

Stivarga / regorafenib for previously treated metastatic colorectal cancer as of February 2023

MARA Rating Company December 16, 2025

Ryeqo for treating moderate to severe symptoms of uterine fibroids as of October 2022

MARA Rating Company December 16, 2025